SEC Comment Letter 0000000000-23-011694 to IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC.
Date: Oct. 25, 2023 · CIK: 0001834105 · Accession: 0000000000-23-011694
AI Filing Summary & Sentiment
File numbers found in text: 333-275062
Letter
United States securities and exchange commission logo October 25, 2023 Frank Heuszel Chief Executive Officer and Director Impact BioMedical, Inc. 1400 Broadfield Blvd. , Suite 130 Houston, TX 77084 Re:Impact BioMedical, Inc. Registration Statement on Form S-1 Filed October 17, 2023 File No. 333-275062 Dear Frank Heuszel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Darrin Ocasio, Esq.
Show Raw Text
United States securities and exchange commission logo
October 25, 2023
Frank Heuszel
Chief Executive Officer and Director
Impact BioMedical, Inc.
1400 Broadfield Blvd. , Suite 130
Houston, TX 77084
Re:Impact BioMedical, Inc.
Registration Statement on Form S-1
Filed October 17, 2023
File No. 333-275062
Dear Frank Heuszel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Darrin Ocasio, Esq.